Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)

Core Insights - Belite Bio, Inc is participating in the Asia-Pacific Academy of Ophthalmology (APAO) 2026 Congress to present findings related to its drug tinlarebant for Stargardt disease type 1 (STGD1) [1][2] Company Overview - Belite Bio is a clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases, including STGD1 and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD) [8] - The lead candidate, tinlarebant, is designed to reduce the accumulation of bisretinoid toxins in the eye, which are linked to retinal diseases [8] Upcoming Presentations - The company will present topline results from the Phase 3 DRAGON study of tinlarebant for adolescents with STGD1 during the APAO Congress [2][3] - An oral presentation is scheduled for February 6, 2026, and a sponsored lunch symposium will take place on February 7, 2026 [3] Exhibition Details - Belite Bio will have an exhibition booth at the APAO Congress from February 5-7, 2026, located at Hall 5E, Booth 5E-C03 [4] About Tinlarebant - Tinlarebant is an oral therapy that aims to reduce vitamin A-based toxins causing retinal disease in STGD1 and contributes to disease progression in GA [4] - The drug has received multiple designations, including Breakthrough Therapy and Fast Track in the U.S., and Orphan Drug Designation in the U.S., Europe, and Japan [4] About Stargardt Disease Type 1 (STGD1) - STGD1 is the most common inherited macular dystrophy, leading to central vision loss due to mutations in the ABCA4 gene [5] - There are currently no FDA-approved treatments for STGD1, highlighting the unmet medical need in this area [5]